Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The study 'Safety and Efficacy of Paricalcitol for Reduction of Proteinuria in Kidney
Transplant Recipients' is designed to assess the effects of paricalcitol in kidney transplant
recipients with proteinuria.
It is a single centre, randomized, placebo-controlled, double-blind clinical trial that tests
the hypothesis that 24 weeks' treatment with paricalcitol compared to placebo will result in
a decrease in urinary protein excretion in recipients of a kidney transplant at least three
months after transplantation. Additionally, the effects of paricalcitol on albuminuria,
estimated glomerular filtration rate, and blood pressure will be investigated.